The amino acid sequence of the extracellular domain of matrix protein 2 (M2e) is conserved among all subtypes of influenza A viruses. Therefore, the M2e peptide can be considered as a target antigen for the development of a universal influenza vaccine. We evaluated the effects of adding cysteine residues to a peptide of amino acids 2–24 of M2e. Mice immunized with some of these peptides containing one, two, three, four, or five extra cysteines displayed enhanced antibody titers to M2e. In addition, immunization with a peptide containing three extra cysteines, along with an aluminum adjuvant, protected mice more effectively against a lethal influenza virus challenge than the original M2e peptide. These results indicated that an M2e peptide containing additional cysteine residues could be a universal influenza vaccine candidate even without the addition of strong adjuvants.
Get full access to this article
View all access options for this article.
References
1.
BessaJ, SchmitzN, HintonHJ, SchwarzK, JegerlehnerA, BachmannMF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: Implications for vaccine design. Eur J Immunol, 2008; 38:114–126.
2.
De FiletteM, MartensW, RooseKet al.An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem, 2008; 283:11382–11387.
3.
DenisJ, Acosta-RamirezE, ZhaoYet al.(2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine, 2008; 26:3395–3403.
4.
EbrahimiSM, DabaghianM, TebianianM, JaziMH. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology, 2012; 430:63–72.
5.
EbrahimiSM, TebianianM. Influenza A viruses: Why focusing on M2e-based universal vaccines. Virus Genes, 2011; 42:1–8.
6.
EliassonDG, El BakkouriK, SchönKet al.CTA1–M2e–DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine, 2008; 26:1243–1252.
7.
FanJ, LiangX, HortonMSet al.Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine, 2004; 22:2993–3003.
8.
FengJ, ZhangM, MozdzanowskaKet al.Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J, 2006; 3:102.
9.
FergusonM, RisiG, DavisMet al.Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis, 2012; 205:733–744.
10.
FiersW, De FiletteM, El BakkouriKet al.(2009) M2e-based universal influenza A vaccine. Vaccine, 2009; 27:6280–6283.
11.
FouchierRA, MunsterV, WallenstenAet al.Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol, 2005; 79:2814–2822.
12.
HugheyPG, RobertsPC, HolsingerLJ, ZebedeeSL, LambRA, CompansRW. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Virology, 1995; 212:411–421.
13.
HuleattJW, NakaarV, DesaiPet al.Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 2008; 26:201–214.
14.
JaziMH, DabaghianM, TebianianM, GharagozlouMJ, EbrahimiSM. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res, 2012; 167:219–225.
LaddyDJ, YanJ, KutzlerMet al.Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One, 2008; 3:e2517.
17.
LambRA, ZebedeeSL, RichardsonCD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell, 1985; 40:627–633.
18.
LindbladEB. Aluminum compounds for use in vaccines. Immunol Cell Biol, 2004; 825:497–505.
19.
LiuW, ZouP, ChenYH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett, 2004; 93:131–136.
20.
MarrackP, McKeeAS, MunksMW. Towards an understanding of the adjuvant action of aluminum. Nat Rev Immunol, 2009; 9:287–293.
21.
MatsudaJ, KaminakaK, NozakiC. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. Biochem Biophys Res Commun, 2009; 382:149–152.
22.
MozdzanowskaK, MaieseK, FurchnerM, GerhardW. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology, 1999; 254:138–146.
23.
MozdzanowskaK, FengJ, EidMet al.Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine, 2003; 21:2616–2626.
24.
NeirynckS, DerooT, SaelensX, VanlandschootP, JouWM, FiersW. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med, 1999; 5:1157–1163.
25.
SchnellJR, ChouJJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008; 451:591–595.
26.
StraightTM, OttoliniMG, PrinceGA, EichelbergerMC. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol J, 2008; 5:44
27.
TreanorJJ, TierneyEL, ZebedeeSL, LambRA, MurphyBR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol, 1990; 64:1375–1377.
28.
WolfAI, MozdzanowskaK, WilliamsKLet al.Vaccination with M2e-based multiple antigenic peptides: Characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One, 2011; 6:e28445.
29.
ZebedeeSL, LambRA. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol, 1988; 62:2762–2772.
